ArticleCancer immunology, immunotherapy : CII2026
Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung Cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundβ-catenin-independent Wnt signaling plays a role in lung carcinogenesis, but its impact on prognosis and immune response in Non-Small Cell Lung Cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICI) remains unclear. This study evaluates the prognostic significance of Wnt5a and Wnt5b and their role in immune modulation.
methodsA prospective cohort of 52 consecutive advanced NSCLC patients receiving first-line ICI therapy was analyzed. Plasma samples were analysed using ELISA to quantify Wnt5a/Wnt5b. PBMCs were stimulated with PHA ± Pembrolizumab and co-cultured with recombinant Wnt5a or NSCLC explants. Wnt signaling inhibition was achieved using porcupine inhibitors (IWP-2/IWP-4) or neutralizing Wnt5a antibody. CD8 + T cell activation and cytokine production (INFγ, IL-6, IL-10) were measured by flow cytometry and ELISA.
resultsWe observed that Wnt5a levels were significantly elevated in NSCLC patients and correlated with poor tumor response (RR = 2.4, p = 0.05) and shorter progression-free survival (Hazard Ratio (HR) = 2.77; 95% CI 1.11-6.88; p = 0.028.). In vitro, Wnt5a suppressed CD8 + T cell activation and INFγ production. These immunosuppressive effects were reversed by Wnt5a inhibitors, highlighting their potential as therapeutic agents to improve immune response in NSCLC patients receiving ICI therapy.
conclusionsOverall, high Wnt5a correlates with immune suppression and poor ICI response, suggesting its potential as a predictive biomarker and therapeutic target in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.